Biodexa Pharmaceuticals Plc

Healthcare · Biotechnology · United Kingdom

Last price 3.43 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 441.21K

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse m...